ArticleJournal of Crohn's & colitis2026
BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype.
Article in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND AND
aimsInflammatory bowel diseases (IBDs) are characterized by chronic intestinal inflammation, in which inflammatory fibroblasts contribute to epithelial damage and amplification of mucosal inflammation. However, the molecular mechanisms regulating their pathogenic activity remain incompletely understood. This study investigated the role of the epigenetic reader BRD4 in the differentiation and function of IL-13RA2-expressing inflammatory fibroblasts in IBD.
methodsSingle-cell RNA sequencing datasets from IBD patients and controls were analyzed to define BRD4 expression across stromal populations. Protein expression was validated by immunofluorescence and flow cytometry in intestinal tissues and primary fibroblasts. Primary fibroblasts from IBD patients were stimulated with interleukin (IL)-4, IL-13, and tumor necrosis factor-alpha (TNF-α) to induce an inflammatory phenotype, and BRD4 function was assessed using the BRD4-targeting PROTAC AT1. Cytokine and chemokine expression was evaluated by RNA sequencing, real-time polymerase chain reaction (PCR), and ELISA, while neutrophil chemotaxis assays assessed the functional effects of fibroblast-derived mediators.
resultsBRD4 was significantly upregulated in inflammatory fibroblasts from IBD patients compared with other stromal subsets and controls. Inflamed tissues showed enrichment of BRD4⁺ and IL-13RA2⁺ fibroblasts. In vitro, cytokine stimulation induced IL-13RA2 expression in the majority of fibroblasts, all of which co-expressed BRD4. BRD4 degradation significantly reduced the proportion of IL-13RA2⁺ fibroblasts. BRD4⁺ fibroblasts exhibited a pro-inflammatory transcriptional profile, including CCL2, CXCL1, CXCL2, IL-11, IL-24, IL-32, and CSF3. Degradation of BRD4 markedly decreased the expression of these mediators and reduced neutrophil migration.
conclusionsBRD4 contributes to cytokine-induced inflammatory activation and pro-inflammatory functions of intestinal fibroblasts in IBD. Targeting BRD4 may represent a potential strategy to modulate stromal cell-driven inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.